GIP and obesity due to melanocortin 4 receptor deficiency: More recently, semaglutide in the STEP-1 trial produced mean weight losses of approximately 15% in individuals living with obesity [4] in a 68-week randomised trial of 1961 adults with overweight or obesity. The dual GIP/GLP-1 agonist tirzepatide in SURMOUNT-1 achieved reductions exceeding 20% in some participants [5], as demonstrated in a 72-week, phase 3 trial enrolling 2539 adults with obesity. These drugs have paved the way for the efficient invention of even more efficacious drugs in the future.